Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.39 |
| ▸ | CHRNG | P07510 | 1/20 | 0.39 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | CHRND | Q07001 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9635880 | 0.81 | CYP3A4 (0.48) | PARP1CYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL12799168 | 0.77 | CHRNA7 (0.36) | SLC6A2SLC6A4SLC6A3CHRNA1CHRNG | |
| SCHEMBL6602202 | 0.77 | TSHR (0.45) | PARP1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL6601746 | 0.77 | SLC6A2 (0.42) | PARP1SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL7670262 | 0.76 | HTR2C (0.56) | HTR2CCYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL16136704 | 0.76 | HTR2C (0.49) | PARP1HTR2CSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL4213803 | 0.75 | JAK3 (0.49) | PARP1HTR2CCYP2D6SLC6A2SLC6A4 | |
| SCHEMBL30776200 | 0.75 | JAK3 (0.49) | PARP1HTR2CCYP2D6SLC6A2SLC6A4 | |
| SCHEMBL1663055 | 0.75 | JAK3 (0.49) | PARP1HTR2CCYP2D6SLC6A2SLC6A4 | |
| SCHEMBL2781842 | 0.75 | HTR2C (0.47) | PARP1HTR2CSLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | PARP1 2606/4885HTR2C 3/4885CYP2D6 571/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | PARP1 2606/4885HTR2C 3/4885CYP2D6 571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.